Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
Intrinsic Value
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. [ Read More ]
The intrinsic value of one
ONCO3
stock under the Base Case scenario is
16.16
BRL.
Compared to the current market price of 5.64 BRL,
Oncoclinicas do Brasil Servicos Medicos SA
is
Undervalued by 65%.
Oncoclinicas do Brasil Servicos Medicos SA's market capitalization is 2.9B BRL.
ONCO3 stock price is 5.64 BRL.
ONCO3 stock price (5.64 BRL) is 65% less than its Intrinsic Value (16.16 BRL).
ONCO3 stock price (5.64 BRL) is 76% less than its Relative Value (23.96 BRL). Open Relative Valuation
ONCO3 has upside potential of 201% compared to the average analyst price target.
Open Wall St Estimates
ONCO3's ROE (Return on Equity) for the past 12 months is positive and is equal to 10%.
ONCO3's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
ONCO3 has positive Operating Income for the last twelve months.
ONCO3's ROIC (Return on Invested Capital) has decreased in the last 3 years from 17% to 11%.
ONCO3's long-term assets (9B BRL) exceed its long-term liabilties (7B BRL).
ONCO3 has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
ONCO3's Revenue has grown by an exceptional 34% over the past 12 months.
ONCO3's Revenue is forecast to grow at a rate of 18% per year over the next 3 years.
ONCO3's short-term assets (3B BRL) exceed its short-term liabilties (2B BRL).
ONCO3 has positive Net Income for the last twelve months.
ONCO3's D/E (Debt to Equity) is equal to 1.77.
ONCO3 has positive Gross Profit for the last twelve months.
ONCO3's ROE (Return on Equity) has significantly increased in the last 3 years from -35% to 10%.
ONCO3's Revenue has been growing by an exceptional 39% per year for the last 3 years.
ONCO3's Altman Z-Score is very low and is equal to 1.62.
ONCO3 has positive Net Debt. This means that the company has more debt (4B BRL) than cash and short-term investments (761m BRL).
ONCO3 has negative Free Cash Flow for the last twelve months.
ONCO3 has very high three-year average ROE (Return on Equity): 48%. The company is very efficient at transforming stockholders' equity into net income.
ONCO3 generates enough operating income (757m BRL) to cover interest payments on its debt (491m BRL).
Valuation Backtest
Oncoclinicas do Brasil Servicos Medicos SA
Run backtest to discover the historical profit from buying and selling
ONCO3
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Oncoclinicas do Brasil Servicos Medicos SA
Balance Sheet Decomposition
Oncoclinicas do Brasil Servicos Medicos SA
| Current Assets | 3.1B |
| Cash & Short-Term Investments | 761.4m |
| Receivables | 2.1B |
| Other Current Assets | 279.9m |
| Non-Current Assets | 6.1B |
| Long-Term Investments | 106.2m |
| PP&E | 1.2B |
| Intangibles | 4.2B |
| Other Non-Current Assets | 543.8m |
| Current Liabilities | 1.8B |
| Accounts Payable | 957.5m |
| Accrued Liabilities | 281.3m |
| Other Current Liabilities | 577.7m |
| Non-Current Liabilities | 5.1B |
| Long-Term Debt | 4.1B |
| Other Non-Current Liabilities | 982.2m |
Earnings Waterfall
Oncoclinicas do Brasil Servicos Medicos SA
|
Revenue
|
5.5B
BRL
|
|
Cost of Revenue
|
-3.6B
BRL
|
|
Gross Profit
|
1.9B
BRL
|
|
Operating Expenses
|
-1.2B
BRL
|
|
Operating Income
|
756.5m
BRL
|
|
Other Expenses
|
-532.9m
BRL
|
|
Net Income
|
223.6m
BRL
|
Free Cash Flow Analysis
Oncoclinicas do Brasil Servicos Medicos SA
ONCO3 Profitability Score
Profitability Due Diligence
Oncoclinicas do Brasil Servicos Medicos SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Oncoclinicas do Brasil Servicos Medicos SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
ONCO3 Solvency Score
Solvency Due Diligence
Oncoclinicas do Brasil Servicos Medicos SA's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Oncoclinicas do Brasil Servicos Medicos SA's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ONCO3 Price Targets Summary
Oncoclinicas do Brasil Servicos Medicos SA
According to Wall Street analysts, the average 1-year price target for
ONCO3
is 16.97 BRL
with a low forecast of 10.1 BRL and a high forecast of 24.15 BRL.
Shareholder Return
ONCO3 Price
Oncoclinicas do Brasil Servicos Medicos SA
| Average Annual Return | -44.91% |
| Standard Deviation of Annual Returns | 3.42% |
| Max Drawdown | -78% |
| Market Capitalization | 2.9B BRL |
| Shares Outstanding | 507 910 547 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Oncoclinicas do Brasil Servicos Medicos SA
Country
Industry
Market Cap
Dividend Yield
Description
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Contact
IPO
Employees
Officers
The intrinsic value of one
ONCO3
stock under the Base Case scenario is
16.16
BRL.
Compared to the current market price of 5.64 BRL,
Oncoclinicas do Brasil Servicos Medicos SA
is
Undervalued by 65%.
You don't have any saved screeners yet
